Neta Batscha

Neta Batscha is a biotech investor and operator who built her investing career at RA Capital Management, a Boston-based, science-driven investment firm focused on healthcare and life sciences. She joined RA Capital around 2013 and held progressively senior roles there, working as an Equity Analyst specializing in biotechnology, a TechAtlas associate (RA Capital's in-house research engine that maps disease and competitive landscapes), and ultimately a Venture Associate. In that venture role she led due diligence on private life-science investments and helped establish the firm's Texas operations, extending its presence beyond Boston.

During her RA Capital tenure she served as a board observer on several of the firm's portfolio companies, including Satsuma Pharmaceuticals (board observer ~2017–2020), Lyra Therapeutics (~2018–2020), and Sojournix — giving her direct, governance-level exposure to clinical-stage therapeutics companies as they advanced and, in some cases, went public.

She holds a BS in Biology (Course 7) from the Massachusetts Institute of Technology (2008–2012), and her earlier research experience spans MIT, Tel Aviv University, and clinical-research settings, which underpins her scientific-diligence orientation as an investor.

After RA Capital, Batscha served as VP of Biotech Investment Underwriting at The Beneficient Company Group (May 2020–September 2021), then moved into an operating role as VP — and later SVP — of Corporate Strategy and Operations at Paragon Therapeutics, an antibody-focused therapeutics company, where she has worked since September 2021. Her racap.com email and Boston (617) phone number reflect her RA Capital affiliation.

• Invests in biotechnology and therapeutics companies, evaluated through deep scientific and clinical diligence rather than generalist consumer/tech metrics.
• Active across early-stage private life-science rounds through crossover — RA Capital's model spans seed/venture financings into public-market positions.
• Diligence-led approach rooted in TechAtlas-style landscape mapping: assessing a program's mechanism, competitive set, and clinical differentiation before committing.
• Looks for companies with credible scientific rationale and a path through clinical development, consistent with her board-observer work at clinical-stage drug developers.
• Geographically open beyond the Boston biotech hub — she personally helped extend RA Capital's reach into Texas.